Paragon Bioservices Awarded $4.99 Million US Army Contract to Assist with Ebola Vaccine Development
Paragon Bioservices, a Baltimore-based CMO focused on the contract research, process development, and manufacturing of biologics, has been awarded a $4.99 million contract to assist the US Army Medical Research Institute for Infectious Diseases (USAMRIID) in its vaccine development efforts.
Paragon Bioservices, a Baltimore-based CMO focused on the contract research, process development, and manufacturing of biologics, has been awarded a $4.99 million contract to assist the US Army Medical Research Institute for Infectious Diseases (USAMRIID) in its vaccine development efforts.
The USAMRIID project involves process development and scale-up production of virus-like particle (VLP) vaccines against Ebola Zaire, Ebola Sudan, and Marburg viruses to support ongoing preclinical evaluation of efficacy, potency, and safety of these Filovirus vaccine candidates. Using its extensive VLP production and purification expertise, Paragon will develop a large-scale mammalian process suitable for future GMP manufacturing.
Ebola and Marburg viruses are a serious global health threat. They cause hemorrhagic fever and have up to a 90% fatality rate in humans. Currently, there are no vaccines or therapies available for these viruses. They commonly are spread through blood and bodily fluids of infected patients who frequently succumb to hypovolemic shock. Both viruses are potential agents of biological warfare or terrorism because both also are infectious by aerosol.
The Solution Lies with SOLBIOTE™: Achieving Sustainability, a Growing Focus in Biopharma
October 28th 2024The nexus between biopharmaceuticals and sustainability is seemingly far apart, however, it is increasingly recognized as an inevitable challenge. It is encouraged to take a sustainable approach to reducing the environmental impact of the production and supply of medicines while improving people's health; delivering the well-being of people and the planet. Yosuke Shimojo (Technical Value Support Section Manager, Nagase Viita) will unveil how SOLBIOTE™, a portfolio of injectable-grade saccharide excipients, would be a key for the biopharmaceutical development and achieving sustainability for a better future of the industry.
